<DOC>
	<DOCNO>NCT02415192</DOCNO>
	<brief_summary>Levacalm Tab . approve Jul 2013 MFDS South Korea . Levacalm Tab . combination drug Valsartan angiotensin II receptor blocker Lercanidipine Calcium channel blocker . It new drug combination Valsartan Lercanidipine . Thus , 's enough safety data efficacy data define clinical study . Also , many combination drug valsartaa amlodipine widely use market . LGLS compare safety ( adverse event especially low leg edema ) efficacy ( blood pressure pulse ) Levacalm Valsartan/amlodipine combination drug study .</brief_summary>
	<brief_title>Observational Study Evaluate Safety Efficacy Levacalm Tab . Versus Valsartan/Amlodipine Combination Therapy Essential Hypertension Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>patient age 19 essential hypertension Those meet inclusion criterion , fall follow 3 case determine investigator prescribe Levacalm Valsartan/Amlodipine combination : 1. ca n't maintain blood pressure antihypertensive drug . 2. diagnosed hypertension stage 2 . ( DBP high 160mmHg SBP high 100mmHg ) 3. fall following : cardiovascular disease , Cerebrovascular disease , chronic Renal disease , diabetes mellitus , peripheral vascular disease Those inform purpose , method , effect etc . study sign informed consent form . 1 . Those included contraindication study drug follow information use product 2 . Those is/will participate drug clinical trial 3 . Those adminitrated antihypertensive drug beside levacalm Valsartan/amlodipine combination drug . 4 . Those judged invesigator ineligible clinical study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>safety data</keyword>
	<keyword>hypertension therapy</keyword>
</DOC>